In addition, tumors with BRCA 1/2 mutations, in particular breast cancers, also seem to have higher expression of PD-L1, inflammatory interferon-γ signatures, and stronger infiltration by immune cells, associated with higher mutational load (TMB) [35]. This evidence concerns the gene CD274 and breast cancer.